-
1Academic Journal
Authors: D. B. Nizheharodava, N. A. Marozava, G. I. Ivanchyk, S. S. Kulinich, J. V. Kolyadich, M. M. Zafranskaya, Д. Б. Нижегородова, Н. А. Морозова, Г. И. Иванчик, С. С. Кулинич, Ж. В. Колядич, М. М. Зафранская
Source: Medical Immunology (Russia); Том 26, № 5 (2024); 933-940 ; Медицинская иммунология; Том 26, № 5 (2024); 933-940 ; 2313-741X ; 1563-0625
Subject Terms: полипозный риносинусит, interferons, tumor microenvironment, sinonasal neoplasms, inverted papilloma, polypous rhinosinusitis, интерфероны, опухолевое микроокружение, синоназальные новообразования, инвертированная папиллома
File Description: application/pdf
Relation: https://www.mimmun.ru/mimmun/article/view/3100/2006; De Meulenaere A., Vermassen T., Aspeslagh S., Vandecasteele K., Rottey S., Ferdinande L. TILs in head and neck cancer: ready for clinical implementation and why (not)? Head Neck Pathol., 2017, Vol. 11, no. 3, pp. 354-363.; Del Prete A., Salvi V., Soriani A., Laffranchi M., Sozio F., Bosisio D., Sozzani S. Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell. Mol. Immunol., 2023, Vol., 20, no. 5, pp. 432-447.; Diao J., Mikhailova A., Tang M., Gu H., Zhao J., Cattral M.S. Immunostimulatory conventional dendritic cells evolve into regulatory macrophage-like cells. Blood, 2012, Vol. 119, no. 21, pp. 4919-4927.; Eide J.G., Welch K.C., Adappa N.D., Palmer J.N., Tong C.C.L. Sinonasal inverted papilloma and squamous cell carcinoma: contemporary management and patient outcomes. Cancers (Basel), 2022, Vol. 14, no. 9, 2195. doi:10.3390/cancers14092195.; García-Marín R., Reda S., Riobello C., Cabal V.N., Suárez-Fernández L., Vivanco B., Álvarez-Marcos C., López F., Llorente J.L., Hermsen M.A. Prognostic and therapeutic implications of immune classification by CD8+ tumor-infiltrating lymphocytes and PD-L1 expression in sinonasal squamous cell carcinoma. Int. J. Mol. Sci., 2021, Vol. 22, no. 13, 6926. doi:10.3390/ijms22136926.; Gu J.T., Claudio N., Betts C., Sivagnanam S., Geltzeiler M., Pucci F. Characterization of the tumor immune microenvironment of sinonasal squamous-cell carcinoma. Int. Forum Allergy Rhinol., 2022, Vol. 12, no. 1, pp. 39-50.; Gulubova M. Myeloid and plasmacytoid dendritic cells and cancer – new insights. Open Access Maced. J. Med. Sci., 2019, Vol. 7, no. 19, pp. 3324-3340.; Gupta Y.H., Khanom A., Acton S.E. Control of dendritic cell function within the tumour microenvironment. Front. Immunol., 2022, Vol. 10, no. 13, 733800. doi:10.3389/fimmu.2022.733800.; Mitchell D., Chintala S., Dey M. Plasmacytoid dendritic cell in immunity and cancer. J. Neuroimmunol., 2018, Vol. 322, pp. 63-73.; Musella M., Galassi C., Manduca N., Sistigu A. The yin and yang of type I IFNs in cancer promotion and immune activation. Biology (Basel), 2021, Vol. 10, no. 9, 856. doi:10.3390/biology10090856.; Plesca I., Müller L., Böttcher J.P., Medyouf H., Wehner R., Schmitz M. Tumor-associated human dendritic cell subsets: phenotype, functional orientation, and clinical relevance. Eur. J. Immunol., 2022, Vol. 52, no. 11, pp. 1750-1758.; Sittig S.P., De Vries I.J., Schreibelt G. Primary human blood dendritic cells for cancer immunotherapy – tailoring the immune response by dendritic cell maturation. Biomedicines, 2015, Vol. 3, no. 4, pp. 282-303.; Sprooten J., Agostinis P., Garg A.D. Type I interferons and dendritic cells in cancer immunotherapy. Int. Rev. Cell. Mol. Biol., 2019, Vol. 348, pp. 217-262.; Wu J., Li S., Yang Y., Zhu S., Zhang M., Qiao Y., Liu Y., Chen J. TLR-activated plasmacytoid dendritic cells inhibit breast cancer cell growth in vitro and in vivo. Oncotarget, 2017, Vol. 8, no. 7, pp. 11708-11718.; Zhou B., Lawrence T., Liang Y. The role of plasmacytoid dendritic cells in cancers. Front. Immunol., 2021, Vol. 12, 749190. doi:10.3389/fimmu.2021.749190.; https://www.mimmun.ru/mimmun/article/view/3100